|Bid||0.4120 x 1300|
|Ask||0.4226 x 2200|
|Day's Range||0.4100 - 0.4300|
|52 Week Range||0.2600 - 4.3000|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Boston-based company said it had a loss of 12 cents per share. Losses, adjusted for stock option expense, were 11 cents per share. The biotech drug developer posted revenue of $105,000 in the period. ...
Salarius Pharmaceuticals announced plans to merge with Boston-based Flex Pharma Inc. (Nasdaq: FLKS).
Houston-based Salarius Pharmaceuticals LLC, a clinical-stage oncology company, will merge with Boston-based Flex Pharma Inc. (Nasdaq: FLKS). The combined company will be named Salarius Pharmaceuticals Inc. and will focus on developing Salarius’ drugs. The deal is expected to close in the first half of 2019, with Flex Pharma stockholders and current Salarius investors owning approximately 19.9 percent and 80.1 percent of the combined company, respectively.
The announcement comes about seven months after Flex Pharma announced it would lay off most of its employees and explore a potential sale or merger after ending a mid-stage trial of its lead drug.
Flex Pharma stock was on the rise today following news of a merger with Salarius Pharmaceuticals. Source: amtec.us.com The deal will have a wholly owned subsidiary of Flex Pharma (NASDAQ:FLKS) merging with Salarius Pharmaceuticals. Once the deal is complete, FLKS will be changing its name to Salarius Pharmaceuticals. When the deal reaches completion, the current management team of Salarius Pharmaceuticals will lead the new company. Flex Pharma's President and CEO William McVicar will also join the company's Board of Directors. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The deal between the two companies will result in holders of Flex Pharma stock having a 19.9% stake in the new company. The remaining will belong to current investors of Salarius Pharmaceuticals. There is also a warrants option for holders of Flex Pharma stock that will allow them an additional 2.4% stake in the company. With the two companies merging to become one, the new focus will be on Salarius Pharmaceuticals pipeline of treatments for orphan cancers and other cancers without treatment options. Money from the combined company is expected to keep it running until mid-2020, which is enough time for it to report "early cohort data from an ongoing Phase 1 Ewing sarcoma trial." * 10 Oversold Stocks Due for a Bounce The deal between Flex Pharma and Salarius Pharmaceuticals already has the unanimous approval from both companies' Board of Directors. It still needs approval from investors in FLKS stock and Salarius Pharmaceuticals, as well as completing other customary closing conditions. If all goes well, the deal is set to close in the first half of 2019. FLKS stock was up 47% as of noon Friday. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Downtrodden Stocks to Fish From the Bottom * 8 Cheap Value Stocks That Just Got More Enticing * 5 Apple Suppliers Hurt by the Guidance Cut As of this writing, William White did not hold a position in any of the aforementioned securities. Compare Brokers The post FLKS News: Flex Pharma Stock Rockets Higher on Salarius Merger appeared first on InvestorPlace.
Embattled Flex Pharma Inc (NASDAQ: FLKS) announced a deal Friday to merge with privately held Salarius Pharma, an oncology company targeting the epigenetic causes of cancer. Following the closing of the deal, Flex shareholders would own about 19.9 percent of the combined company and Salarius shareholders the remaining 80.1 percent. Flex shareholders would also receive a right to receive warrants six months and a day after the closing of the deal, which gives them the option to purchase additional shares.
If you're interested in Flex Pharma, Inc. (NASDAQ:FLKS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
The Boston-based company said it had a loss of 15 cents per share. The biotech drug developer posted revenue of $251,000 in the period. The company's shares closed at 63 cents. A year ago, they were trading ...
This list of stocks was generated by tracking the most popular ticker searches on the Benzinga Pro real-time news platform. Readers can rely on this daily list to offer insight into which stocks retail ...
Flex Pharma Inc (NASDAQ:FLKS), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is FLKS Read More...
Flex Pharma (FLKS) delivered earnings and revenue surprises of -28.21% and 23.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Boston-based company said it had a loss of 50 cents per share. The biotech drug developer posted revenue of $246,000 in the period. The company's shares closed at 83 cents. A year ago, they were trading ...
Flex Pharma’s (FLKS) board approved a plan for corporate restructuring on June 8 in order to reduce the company’s capital structure. Management initiated a process to scout strategic alternatives for enhancing shareholder value, which includes a possible sale or merger of the company. Flex Pharma’s board has established a strategic committee to work in tandem with management to oversee this process.
Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.
U.S. drug developer Flex Pharma Inc said on Wednesday it plans to stop two ongoing mid-stage trials, testing its lead drug to treat neuromuscular diseases, following safety concerns. The drug, FLX-787, was being tested in trials to treat amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth disease, a rare neuromuscular disorder.
U.S. drug developer Flex Pharma Inc said on Wednesday it plans to reduce its workforce by 60 percent, as part of a restructuring, and was ending certain ongoing mid-stage trials. The company will now focus ...